The Ghost in the Syringe: Deconstructing Nanoparticle Claims in Ozempic
The global ascension of semaglutide—marketed predominantly as Ozempic for type 2 diabetes and Wegovy for chronic weight management—marks one of the most consequential pharmacological shifts of the twenty-first century[1]. By mimicking the endogenous incretin hormone GLP-1, it alters human metabolic architecture, gastrointestinal motility, and neurological…